摘要
慢性肾脏病(CKD)患者肾功能恶化,引起继发性甲状旁腺功能亢进以及钙磷代谢紊乱,进一步导致血管钙化等心血管疾病,增加CKD患者发病率及死亡率。传统磷结合剂常含钙、铝成分,降低血磷但不良反应较多。司维拉姆、碳酸镧、SBR759、PA21-1、考来替兰和碱式碳酸镁铁等新型磷结合剂不含钙、铝,具有与传统磷结合剂类似的降低血磷作用,却不升高血钙,为控制高磷血症且减少血管钙化风险提供了治疗前景。
Chronic kidney disease （CKD） can make kidney function worsening,which in turn leads to the loss of phosphate balance and secondary hyperparathyroidism. The loss of phosphate homeostasis can contribute to cardiovascular diseases caused by vascular calcification, and increase the morbidity and mortality in CKD. The traditional phosphate binders almost contain calcium and aluminum, which have many side effects when the hyperphosphatemia is controlled Sevelamer and lanthanum carbonate are non-calcium-or aluminum-based phosphate binders. They have the same effect in controlling the hyperphosphatemia as traditional agents, and what＇s more, they do not result in hypercalcemia, which provide a new future in controlling hyperphosphatemia and at the same time not increasing the risk of vascular calcification.
出处
《肾脏病与透析肾移植杂志》
CAS
CSCD
北大核心
2011年第6期559-564,共6页
Chinese Journal of Nephrology,Dialysis & Transplantation
关键词
慢性肾脏病
磷结合剂
chronic kidney
disease
phosphate binders
